compound introduction
SBI-425 is an orally active and potent TNAP ( tissue-nonspecific alkaline phosphatase ) inhibitor ( IC 50 =16 nM). SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival In Vitro SBI-425 treatment suppresses Foxp3 expression in CD4 + and CD8 + T cells in splenocytes from CLP-injured mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo 1.19 Mouse PK parameters for SBI-425 Compds SBI-425 Cl p (mL/min/kg) 5.14 Vd (L/kg) 1.03 C max (μg/mL) 178 AUC (μg*hr/mL) 848 t 1/2 (hr) 2.3 %F 58 MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:IC50: 16 nM (TNAP)
